Wall Street analysts predict that Eli Lilly and Company (NYSE:LLY) will announce earnings of $1.04 per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Eli Lilly and’s earnings. The lowest EPS estimate is $0.99 and the highest is $1.11. Eli Lilly and posted earnings of $0.88 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.2%. The firm is expected to announce its next earnings results on Tuesday, October 24th.

According to Zacks, analysts expect that Eli Lilly and will report full-year earnings of $4.14 per share for the current year, with EPS estimates ranging from $4.08 to $4.18. For the next fiscal year, analysts anticipate that the business will post earnings of $4.50 per share, with EPS estimates ranging from $4.38 to $4.59. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Eli Lilly and.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the business earned $0.86 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year.

A number of equities analysts have recently commented on the stock. Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a report on Friday. Cowen and Company upped their price objective on shares of Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a report on Monday, April 17th. Sanford C. Bernstein reiterated an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a report on Sunday, May 21st. TheStreet lowered shares of Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. Finally, BMO Capital Markets reissued an “underperform” rating and set a $73.00 target price on shares of Eli Lilly and in a research report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $88.27.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Eli Lilly and Company (NYSE:LLY) to Announce $1.04 EPS” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/analysts-anticipate-eli-lilly-and-company-nyselly-to-announce-1-04-eps.html.

Eli Lilly and (NYSE:LLY) opened at 82.07 on Tuesday. The firm has a market cap of $86.58 billion, a P/E ratio of 35.51 and a beta of 0.34. The stock has a 50 day moving average price of $82.99 and a 200-day moving average price of $81.53. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $86.72.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of LLY. Ronna Sue Cohen boosted its position in shares of Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares during the last quarter. Accredited Investors Inc. raised its stake in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after buying an additional 14 shares during the last quarter. Sunbelt Securities Inc. raised its stake in Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares during the last quarter. Northwest Quadrant Wealth Management LLC raised its stake in Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares during the last quarter. Finally, Pillar Pacific Capital Management LLC raised its stake in Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after buying an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 75.61% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.